Verdict TRUE

TRUE — On December 8, 2023, the FDA approved Casgevy as the first CRISPR-based gene-editing therapy authorized in the United States Is Real

Verified on July 20, 2026

The FDA authorized Casgevy on December 8, 2023, as the first CRISPR-based gene-editing treatment in the United States.

Confidence82%

How strongly independent, cited sources support this verdict.

Claim reviewed

On December 8, 2023, the FDA approved Casgevy as the first CRISPR-based gene-editing therapy authorized in the United States.

Analysis summary

The FDA authorized Casgevy on December 8, 2023, as the first CRISPR-based gene-editing treatment in the United States. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.

Evidence profile

Key findings

The FDA authorized Casgevy on December 8, 2023, as the first CRISPR-based gene-editing treatment in the United States.

Sources

Analyzed across 2 independent publishers

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease Fda

High credibility 78/100

government_primaryInstitutional domain

Revolutionary breakthrough: FDA approves CASGEVY, the first ... - PMC Nih

High credibility 78/100

government_primaryInstitutional domain

Citations

Copy formatted citations from the verified sources above.

Need to verify another claim?

Open Claims Radar to analyze headlines, posts, or links with live source checks.

Verify a claim